NCT03456232

Brief Summary

This study evaluates the effect of high-flux hemodialysis compared to hemodiafiltration on small and moderate molecule substances clearance. Meanwhile, this study evaluates the effect of high-flux hemodialysis compared to hemodiafiltration on cardiac function. In this self matching study, participants will receive high-flux hemodialysis compared to hemodiafiltration.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
40

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Dec 2017

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

December 21, 2017

Completed
2 months until next milestone

First Submitted

Initial submission to the registry

February 27, 2018

Completed
8 days until next milestone

First Posted

Study publicly available on registry

March 7, 2018

Completed
3 days until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 10, 2018

Completed
10 days until next milestone

Study Completion

Last participant's last visit for all outcomes

March 20, 2018

Completed
Last Updated

March 7, 2018

Status Verified

February 1, 2018

Enrollment Period

3 months

First QC Date

February 27, 2018

Last Update Submit

March 5, 2018

Conditions

Keywords

hemodialysishemodiafiltrationend-stage renal disease

Outcome Measures

Primary Outcomes (1)

  • Clearance of moderate molecule substance

    Clearance rate of b2-microglobulin for one dialysis.

    4 hours after dialysis

Secondary Outcomes (1)

  • Left ventricular ejection fraction

    4 hours after dialysis

Study Arms (2)

High-flux hemodialysis

EXPERIMENTAL

High-flux hemodialysis lasting for 4 hours

Other: High-flux hemodialysis

Hemodiafiltration

ACTIVE COMPARATOR

Hemodiafiltration lasting for 4 hours

Other: Hemodiafiltration

Interventions

High-flux hemodialysis using diffusion, ultrafiltration and convection principle to remove harmful substances in the blood and excessive water.

High-flux hemodialysis

Hemodiafiltration is a combination of hemodialysis and hemofiltration with two modes of treatment advantages, both by diffusion and convection principle to remove harmful substances in the blood.

Hemodiafiltration

Eligibility Criteria

Age18 Years - 79 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Subject has end-stage renal disease.
  • Subject has been on regular dialysis treatment for at least 6 months.
  • Subject has autologous vascular access.
  • Subject is offered thrice weekly hemodialysis.
  • Subject is offered 4 hours duration hemodialysis.

You may not qualify if:

  • Infectious disease
  • Poor echocardiographic window that was unsuitable for interpretation

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Guangdong General Hospital

Guangzhou, Guangdong, 510080, China

RECRUITING

MeSH Terms

Conditions

Kidney Failure, Chronic

Interventions

Hemodiafiltration

Condition Hierarchy (Ancestors)

Renal Insufficiency, ChronicRenal InsufficiencyKidney DiseasesUrologic DiseasesFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesMale Urogenital DiseasesChronic DiseaseDisease AttributesPathologic ProcessesPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Renal DialysisRenal Replacement TherapyTherapeuticsSorption DetoxificationHemofiltrationExtracorporeal CirculationSurgical Procedures, Operative

Study Officials

  • Wei Shi, MD,PhD

    Guangdong Provincial People's Hospital

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NON RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

February 27, 2018

First Posted

March 7, 2018

Study Start

December 21, 2017

Primary Completion

March 10, 2018

Study Completion

March 20, 2018

Last Updated

March 7, 2018

Record last verified: 2018-02

Locations